Dallas, Texas 08/29/2014 (FINANCIALSTRENDS) – MannKind Corporation (NASDAQ:MNKD) the bio sector player has definitely set the ball rolling on a positive note, thanks to the new deal it has announced via Sanofi.
The question now is how this will affect the prices of this bio sector player. The tie-up with Sanofi offers exceptional scope for the share prices of Mannkind to see a price rise from current prices of $6.50 into two-digit figures in the following quarters.
But investors and analysts predict that MannKind Corporation (NASDAQ:MNKD) will see massive growth if this stock is held for over a longer period of 3 years over short term.
The company following the announcement of its current deal with Sanofi, has resulted in the $125 million payment as the first step. The company will continue to receive milestone payments for the additional $800 million payment. Therefore, as Sanofi sells Afrezza, it gains the right as well as license offering a 65:35 between Mannkind and Sanofi respectively.
For Sanofi is the gains are in the leveraging the sale of one of the largest drugs seen in over a decade. For Mannkind the gains are in Sanofi’s expertise as a business which has succeeded as a pharma startup.
MannKind Corporation (NASDAQ:MNKD) will continue to see marked profits and share price rise for the unique product it has in Afreeza.
For now as diabetes, the lifestyle disease, spreads like wild fire not only in continental North America but in Asia as well, the sheer market size is staggering for breakthrough drugs such as Afreeza.
Diabetes treatments are evolving and the move to the next level with inhaled insulin has definitely set the standards of delivery of treatment high for this disease currently in the US.